Fate Therapeutics Inc (NASDAQ: FATE) stock enjoyed a major increase of 17.0% on 7/16/24. The shares closed at $4.55. Moreover, exceptionally high trading volume at 341% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months and has risen 45.8% during the last week.
Current PriceTarget Research Rating
FATE’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to be Value Creation neutral.
Fate Therapeutics has a current Value Trend Rating of B (Positive). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Fate Therapeutics has a slightly negative Appreciation Score of 33 but a very high Power Rating of 92, and the Positive Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment